The efficacy of inactivated split respiratory syncytial virus as a vaccine candidate and the effects of novel combination adjuvants

Youri Lee, Eun Ju Ko, Ki Hye Kim, Young Tae Lee, Hye Suk Hwang, Yu Jin Jung, Subbiah Jeeva, Young Man Kwon, Baik Lin Seong, Sang Moo Kang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Clinical trials with alum-adjuvanted formalin-inactivated human respiratory syncytial virus (FI-RSV) vaccine failed in children due to vaccine-enhanced disease upon RSV infection. In this study, we found that inactivated, detergent-split RSV vaccine (Split) displayed higher reactivity against neutralizing antibodies in vitro and less histopathology in primed adult mice after challenge, compared to FI-RSV. The immunogenicity and efficacy of FI-RSV and Split RSV vaccine were further determined in 2 weeks old mice after a single dose in the absence or presence of monophosphoryl lipid A (MPL) + CpG combination adjuvant. Split RSV with MPL + CpG adjuvant was effective in increasing T helper type 1 (Th1) immune responses and IgG2a isotype antibodies, neutralizing activity, and lung viral clearance as well as modulating immune responses to prevent pulmonary histopathology after RSV vaccination and challenge. This study demonstrates the efficacy of Split RSV as an effective vaccine candidate.

Original languageEnglish
Pages (from-to)100-108
Number of pages9
JournalAntiviral Research
Volume168
DOIs
Publication statusPublished - 2019 Aug

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Virology

Fingerprint Dive into the research topics of 'The efficacy of inactivated split respiratory syncytial virus as a vaccine candidate and the effects of novel combination adjuvants'. Together they form a unique fingerprint.

  • Cite this